澳门葡京网赌游戏将在EASD 2015上展示其糖尿病产品组合和临床前研究的综合数据

Friday, 11 September 2015

澳门葡京网赌游戏(AstraZeneca)今天宣布，该公司糖尿病研发的54项摘要将在斯德哥尔摩举行的第51届欧洲糖尿病研究协会(EASD)年会上发表, 瑞典, 14-18 September 2015.

报告将包括一些用于治疗2型糖尿病的获批产品的数据, including Forxiga^® (dapagliflozin), Onglyza^® (saxagliptin), Bydureon^® (once-weekly exenatide extended-release for injectable suspension) and Byetta^® (exenatide) injection, as well as data on the investigational combination of saxagliptin and dapagliflozin, which is currently being reviewed by the regulatory authorities in the US and EU. 另外, 几篇代表澳门葡京网赌游戏早期和临床前研究的摘要探讨了解决糖尿病潜在病理生理的新途径和模式.

Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases, Global 药物 Development, 他说:“澳门葡京赌博游戏在EASD上展示的研究的广度和深度表明了澳门葡京赌博游戏对开发创新糖尿病治疗方法的持续承诺. 澳门葡京赌博游戏相信这些数据加强了澳门葡京赌博游戏的关注，帮助医疗保健提供者和2型糖尿病患者更快地达到治疗目标.”

评估患者获益和联合治疗方法的效果以及除降低HbA1c外的其他效果的数据:

• Nationwide study examining patient characteristics, 瑞典2型糖尿病人群的治疗和流行/发病率(海报#360), Tuesday 15 September, 12:30-13:30 CET)
• 评估在英国常规初级保健中接受达格列净治疗的T2D患者的HbA1c和体重降低(海报#737), Tuesday 15 September, 13:45-14:45 CET)
• 沙格列汀和达格列净加用二甲双胍与序贯加用三联疗法的安全性比较(Poster #741), Wednesday 16 September, 12:30-13:30 CET)
• 德国的一项研究评估了与磺脲类药物相关的治疗特征和结果. metformin in incident T2D patients (Oral #130, Wednesday 16 September, 16:00-17:30 CET)
• Effects of dapagliflozin on albuminuria in hypertensive diabetic patients (Oral #185, Thursday September 17, 15:30-17:00 CET)

真实世界和汇总数据调查长期效果和患者体验，以进一步开发澳门葡京赌博游戏药物的临床概况:

• 长效GLP-1受体激动剂和短效GLP-1受体激动剂上消化道不良事件的比较(口服#15), Tuesday 15 September, 10:45-12:15 CET)
• 三个试验的汇总分析，评估每周一次的艾塞那肽三年的疗效和安全性(Poster #770), Tuesday 15 September, 12:30-13:30 CET)
• Analysis of dapagliflozin effects on long-term HbA1c improvements and weight (Poster #740, Wednesday 16 September, 12:30-13:30 CET)
• 比较患者每周一次使用艾塞那肽和每天一次使用利拉鲁肽的依从性(海报#795), Wednesday 16 September, 13:45-14:45 CET)

探索新途径、潜在机制和治疗方法的研究性新数据:

• Effects of beta-3 agonism on total body weight and glucose tolerance (Oral #23, Tuesday 15 September, 10:45-12:15 CET)
• 研究沙格列汀和达格列净联合治疗对β细胞功能和胰岛素水平的影响(海报#731), Tuesday 15 September, 13:45-14:45 CET)
• 一种新型MCH受体1激动剂对胰岛素抵抗的临床前模型影响(海报#655), Wednesday 16 September, 13:45-14:45 CET)
• 达格列净对小鼠α细胞胰高血糖素分泌影响的评估(口服# 183), Thursday 17 September, 15:30-17:00 CET)

The complete list of AstraZeneca data presentations can be accessed on the EASD website 在这里.

NOTES FOR EDITORS

About Type 2 Diabetes

Type 2 diabetes is a chronic disease characterised by high blood glucose levels, or hyperglycaemia, which results from the body’s ineffective use of insulin. 它占全世界糖尿病患者的90%，并增加心血管疾病和肾衰竭的风险. 据估计，全球有超过3.82亿人受到影响，预计到2035年将超过5.92亿人. 约77%的糖尿病患者生活在低收入和中等收入国家，1.79亿糖尿病患者未得到诊断. 据估计，根据专业协会和糖尿病管理倡导组织制定的指南，超过一半的2型糖尿病患者没有达到推荐的HbA1c目标. The costs and consequences of diabetes are immense globally, resulting in at least USD 612 billion dollars in healthcare expenditures and causing 4.9 million deaths – one person every seven seconds – in 2014.

About AstraZeneca in Diabetes

澳门葡京网赌游戏(AstraZeneca)正在推动科学发展，开发改变生活的药物，旨在减轻全球糖尿病负担和并发症. Driven to redefine outcomes for diabetes patients, our current portfolio consists of the three newest classes of non-insulin, 支持个体化治疗方法的抗糖尿病治疗:SGLT-2抑制剂, GLP-1 receptor agonists and DPP-4 inhibitors. 澳门葡京赌博游戏对糖尿病的承诺体现在澳门葡京赌博游戏全球临床研究项目的深度和广度上. 这一承诺促进了对澳门葡京赌博游戏的糖尿病药物在广大患者群体中的治疗效果的理解, 以及探索联合治疗方法，使更多患者在疾病进展早期获得治疗成功. Our ambition is to reduce the long-term impact of diabetes. As a core strategic area for the company, 澳门葡京赌博游戏将研发重点放在不同人群和具有显著合并症的患者身上, such as cardiovascular disease, 心脏衰竭, 肥胖, non-alcoholic steatohepatitis (NASH), and chronic kidney disease.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, 代谢, 呼吸, 炎症, 自身免疫性, 肿瘤学, infection and neuroscience diseases. 澳门葡京网赌游戏在100多个国家开展业务，其创新药物被全球数百万患者使用. For more information please visit: www.澳门葡京网赌游戏.com.

联系人